IMGT Corporation Limited Logo

IMGT Corporation Limited

Develops a drug delivery platform using ultrasound and nanotech for oncology.

456570 | KO

Overview

Corporate Details

ISIN(s):
KR7456570001
LEI:
Country:
South Korea
Address:
경기도 성남시 분당구 돌마로 172, 성남시
Sector:
Mining and quarrying
Industry:
Mining of non-ferrous metal ores

Description

IMGT Corporation Limited is a clinical-stage biotechnology company specializing in the development of a proprietary drug delivery platform for intractable diseases. Founded in 2010, the company's core technology integrates focused ultrasound with nanotechnology-based medicines to enhance the targeted delivery of therapeutic agents, including gene therapies and immunotherapy solutions. This innovative approach is designed to overcome biological barriers, enabling drugs to more effectively penetrate cancer cells. IMGT's development pipeline includes ultrasonic medical devices and a focus on oncology, with clinical trials underway for treatments such as pancreatic cancer.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-06-04 00:00
Report Publication Announcement
기업설명회(IR)개최결과
Korean 6.6 KB
2025-05-26 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-05-13 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 145.3 KB
2025-05-13 00:00
Major Shareholding Notification
임원ㆍ주요주주특정증권등소유상황보고서
Korean 24.2 KB
2025-05-13 00:00
Share Issue/Capital Change
주식매수선택권부여에관한신고
Korean 14.8 KB
2025-05-12 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 102.6 KB
2025-04-29 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(약식)
Korean 71.2 KB
2025-04-25 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 113.9 KB
2025-04-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제3자배정 유상증자_우선주)
Korean 5.3 KB
2025-04-25 00:00
Share Issue/Capital Change
증권발행결과(자율공시) (제3자배정 유상증자)
Korean 5.2 KB
2025-04-21 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 108.1 KB
2025-04-14 00:00
Share Issue/Capital Change
[기재정정]주요사항보고서(유상증자결정)
Korean 94.0 KB
2025-04-11 00:00
Share Issue/Capital Change
주요사항보고서(유상증자결정)
Korean 89.7 KB
2025-04-07 00:00
Audit Report / Information
사업보고서 (2024.12)
Korean 393.7 KB
2025-03-31 00:00
Audit Report / Information
감사보고서제출
Korean 10.5 KB

Automate Your Workflow. Get a real-time feed of all IMGT Corporation Limited filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for IMGT Corporation Limited

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for IMGT Corporation Limited via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MicroAd,Inc. Logo
Data-driven marketing tech providing DSP and SSP solutions for digital advertising.
Japan
9553
Microwave Chemical Co., Ltd. Logo
Innovating chemical and metal processing with an eco-friendly microwave platform.
Japan
9227
MindWalk Holdings Corp. Logo
AI-powered biotherapeutics firm offering end-to-end antibody discovery and engineering services.
United States of America
HYFT
Minerva Neurosciences, Inc. Logo
A clinical-stage biopharma developing treatments for central nervous system (CNS) diseases.
United States of America
NERV
A think tank providing research, consulting, and ICT solutions to public & private sectors.
Japan
3636
Modalis Therapeutics Corporation Logo
Develops epigenome editing therapies for genetic muscular, heart, and CNS disorders.
Japan
4883
Model Solution Co., Ltd. Logo
One-stop prototyping & low-volume production for IT, electronics, and medical hardware.
South Korea
417970
Modus Therapeutics Holding AB Logo
Developing sevuparin, a polysaccharide for sepsis, septic shock, and chronic inflammation.
Sweden
MODTX
Moleculin Biotech, Inc. Logo
Developing therapies for hard-to-treat tumors (like AML) and viruses.
United States of America
MBRX
Molecure S.A. Logo
Develops first-in-class small molecule drugs for oncology and inflammatory/fibrotic diseases.
Poland
MOC

Talk to a Data Expert

Have a question? We'll get back to you promptly.